Validation, Commissioning & Design Featured Articles

  1. Material Transfer Into A Cleanroom: How To Reduce Contamination Risk At Every Step 4/20/2026

    Evaluate packaging integrity and master wiping techniques to prevent cleanroom contamination. Focus on surface coverage and controlled transfer paths to ensure consistent product safety and quality.

  2. A New Standard For Production Efficiency And GxP Compliance 4/20/2026

    Traditional MES platforms were built for stable environments that no longer exist. Manufacturers are now adopting composable execution architectures to reduce friction and adapt faster.

  3. Why Composable Manufacturing Execution Is Becoming The New Standard 4/20/2026

    Low-code MES promises speed, but agility comes from ownership. Composable, no-code approaches give operations teams the ability to change workflows themselves and respond faster to disruption.

  4. FDA's New Flexible CMC Framework For CGT 4/14/2026

    The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.

  5. MTP And "The Ballroom Concept": Agile Manufacturing For Pharma 4/14/2026

    Modular automation is reshaping manufacturing by enabling faster changeovers, reduced downtime, and built‑in compliance. Learn how the “ballroom” approach helps teams adapt to shifting demand.

  6. Risk Isn't Inevitable: How The Right CDMO Protects Your Programme 4/13/2026

    Risk in outsourced drug development is often created, not inherent. Learn how CDMO structure, continuity, and communication directly affect programme risk, timelines, and outcomes.

  7. How Patent Expirations Will Reshape The Dry Powder Inhaler (PDI) Market 4/10/2026

    Patent expirations on dry powder inhalers are driving rapid market competition. Discover how optimized mechanical dosing speeds scale-up and protects profit margins.

  8. How Asia and Europe Are Reshaping Biologics Manufacturing 4/9/2026

    As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

  9. From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations 4/6/2026

    Learn what regulators are already asking about AI, what quality must mean in this new context, and how organizations can begin building the governance infrastructure.

  10. From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations 4/1/2026

    The FDA’s focus has shifted from tracking quality metrics to promoting quality management maturity. AI/ML is poised to help with efforts, though it introduces additional complexity around data integrity.